TSMC Honors Japanese Chip Equipment Makers With 2025 Supplier Awards 
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance 
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training 
California DMV Proposes New Safety Rules for Autonomous Vehicles After Waymo Incidents 
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market 
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands 
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares 
Nvidia and Groq Strike Strategic AI Inference Licensing Deal 
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy 
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge 
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage 
FDA Approves Mitapivat for Anemia in Thalassemia Patients 
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio 
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector 
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions 
IRVINE, Calif., Sept. 27, 2017 -- Khang & Khang LLP (the “Firm”) announces a securities class action lawsuit against Teva Pharmaceutical Industries Limited (“Teva” or the “Company”) (NYSE:TEVA). Investors who purchased or otherwise acquired shares from November 15, 2016 through August 2, 2017, inclusive (the “Class Period”), are encouraged to contact the Firm before the October 23, 2017 lead plaintiff motion deadline.
If you purchased Teva shares during the Class Period, please contact Joon M. Khang, Esq., of Khang & Khang LLP, 4000 Barranca Parkway, Suite 250, Irvine, CA 92604, by telephone at (949) 419-3834, or by e-mail at [email protected].
There has been no class certification in this case yet. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member as well.
According to the Complaint, throughout the Class Period, Teva issued materially false and/or misleading statements, and/or failed to disclose, that the poor performance of its U.S. generics business resulted in the Company recording a goodwill impairment charge related to the acquisition of Actavis Generics and was a key factor in cutting Teva’s dividend by 75%. When this information was released, shares of Teva fell in value materially, which caused investors harm according to the lawsuit.
If you wish to learn more about this lawsuit, or if you have any questions regarding this notice or your rights, please contact Joon M. Khang, Esq., a prominent litigator for almost two decades, by telephone at (949) 419-3834, or by e-mail at [email protected].
This press release may constitute Attorney Advertising in some jurisdictions.
Contact
Joon M. Khang, Esq.
Telephone: 949-419-3834
Facsimile: 949-225-4474
[email protected]
